title: Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma.
abstract: Malignant melanoma is one of the deadliest forms of skin cancer and its incidence is expected to rise over the next two decades. At present, there are no effective therapies for advanced melanoma. We have previously shown that administration of whole recombinant yeast expressing human MART-1 (hMART-IT) induces protective antimelanoma immunity in a B16F10 transplantable mouse model. In this study, we examine the effectiveness of the hMART-IT vaccine in a congenic strain of genetically engineered mouse model of melanoma, which recapitulates both the underlying genetics and the proper tumor microenvironment of naturally occurring melanoma. Subcutaneous administration of hMART-IT induced cytotoxicity against melanoma cells and antigen-specific production of Th1-specific cytokines by splenocytes. Weekly administration of hMART-IT significantly delayed the development of melanoma and prolonged the survival of mice compared with controls. Although histological analysis demonstrated diffuse infiltration of CD4(+) T cells and CD8(+) T cells, no reduction of regulatory T cells was observed, suggesting that hMART-IT cannot prevent immunotolerance in the tumor microenvironment. This study provides a proof of concept that genetically engineered mouse models lend valuable insights into immunotherapeutics being tested in the preclinical setting.
authors.affiliation: Department of Dermatology, University of Colorado Denver, Aurora, CO 80045, USA.
authors.forename: A
authors.initials: A
authors.lastname: Tanaka
authors.forename: J D
authors.initials: JD
authors.lastname: Jensen
authors.forename: R
authors.initials: R
authors.lastname: Prado
authors.forename: H
authors.initials: H
authors.lastname: Riemann
authors.forename: Y G
authors.initials: YG
authors.lastname: Shellman
authors.forename: D A
authors.initials: DA
authors.lastname: Norris
authors.forename: L
authors.initials: L
authors.lastname: Chin
authors.forename: C
authors.initials: C
authors.lastname: Yee
authors.forename: M
authors.initials: M
authors.lastname: Fujita
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D004195:Disease Models, Animal; D005818:Genetic Engineering; D058965:MART-1 Antigen / Q000276:immunology; D008546:Melanoma, Experimental / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D012441:Saccharomyces cerevisiae / Q000276:immunology; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
chemical_list: D019496:Cancer Vaccines; D058965:MART-1 Antigen; D014614:Vaccines, Synthetic